These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 17967478

  • 1. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Kawabata Y, Ueno Y, Horikawa F, Miyake H, Miki N, Ono M.
    Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
    [Abstract] [Full Text] [Related]

  • 2. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [Abstract] [Full Text] [Related]

  • 3. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [Abstract] [Full Text] [Related]

  • 4. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 5. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E, Maiter D, Donckier J.
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [Abstract] [Full Text] [Related]

  • 6. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 7. Pituitary apoplexy associated with cabergoline therapy.
    Chng E, Dalan R.
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [Abstract] [Full Text] [Related]

  • 8. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [Abstract] [Full Text] [Related]

  • 9. Cabergoline treatment in a case of macroprolactinoma after delivery.
    Falsetti L.
    Acta Eur Fertil; 1995 Nov; 26(3):105-7. PubMed ID: 9098469
    [Abstract] [Full Text] [Related]

  • 10. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C.
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.
    Delgrange E, Daems T, Verhelst J, Abs R, Maiter D.
    Eur J Endocrinol; 2009 May; 160(5):747-52. PubMed ID: 19223454
    [Abstract] [Full Text] [Related]

  • 13. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P, Jaskuła M, Waśko R, Wołuń M, Sowiński J.
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [Abstract] [Full Text] [Related]

  • 14. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T.
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [Abstract] [Full Text] [Related]

  • 15. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL, Wasilewski K, Mazewski CM, Hudgins RJ, Meacham LR.
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [Abstract] [Full Text] [Related]

  • 16. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
    Laboy-Ortiz IE, Velez-Maymí S, Hernán Martínez J, Trinidad R, Mangual M, Sanchez A, Gutierrez M, Mansilla P, Rivera C, Palermo C, de Lourdes Miranda M, Brau R.
    Bol Asoc Med P R; 2016 Jun; 108(1):31-36. PubMed ID: 29193928
    [Abstract] [Full Text] [Related]

  • 17. Non-surgical management of cystic prolactinomas.
    Bahuleyan B, Menon G, Nair S, Rao BR, Easwer HV, Krishna K.
    J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
    [Abstract] [Full Text] [Related]

  • 18. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF.
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
    Kurosaki M, Kambe A, Watanabe T, Fujii S, Ogawa T.
    Neurol Res; 2015 Apr; 37(4):341-6. PubMed ID: 25376133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.